{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001459","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.200026+00:00","generated_at":"2026-05-27T22:39:24.471606+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DSMB recommends Vaxart's COVID-19 Phase 2b trial proceed; norovirus Phase 1 in H1 2025","bullets":["DSMB recommends Phase 2b proceed after review of 30-day safety data from 400-participant sentinel cohort.","Trial to enroll ~10,000 participants pending FDA review and BARDA approval.","Norovirus Phase 1 trial of second-gen vs first-gen constructs to start H1 2025, topline data mid-2025.","New avian influenza vaccine candidate (clade 2.3.4.4b) in preclinical studies.","Cash runway into 2026 supported by BARDA award of up to $460.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001459","json":"https://secwatch.observer/filing/0001437749-25-001459.json","markdown":"https://secwatch.observer/filing/0001437749-25-001459.md","text":"https://secwatch.observer/filing/0001437749-25-001459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001459/0001437749-25-001459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925001459/vxrt20250120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:39:24.471606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}